申请人:Bearsden Bio, Inc.
公开号:US05731348A1
公开(公告)日:1998-03-24
Compounds of a new class of alkyl carboxy amino acid analogs of glutamic acid act as specific regulators of the kainic acid EAA receptor cation channel. These compounds are useful for treating neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders associated with excessive or insufficient activation of the kainic acid subtype of the ionotropic EAA receptors; treating cognitive disorders associated with deactivation, suboptimal activation or over-activation of the kainic acid receptor; alleviating pain and improving and enhancing memory, learning, and associated mental processes. A method for designing novel AMPA or kainic acid receptor agonists or antagonists is also disclosed.
一种新型烷基羧基氨基酸谷氨酸类化合物作为卡因酸EAA受体阳离子通道的特异性调节剂。这些化合物可用于治疗与离子型EAA受体卡因酸亚型过度或不足激活相关的神经学、神经心理学、神经精神学、神经退行性、神经药理学和功能障碍;治疗与卡因酸受体去活化、亚最佳激活或过度激活相关的认知障碍;缓解疼痛和改善和增强记忆、学习和相关的心理过程。还公开了一种设计新型AMPA或卡因酸受体激动剂或拮抗剂的方法。